Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The announcement is a blow to the compounding pharmacies that have made cheaper, off-brand versions of the medication The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over,
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
Lilly's weight-loss, diabetes drugs no longer in shortage, pressuring Hims and Hers' stock
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding manufacturing.
England's NHS to offer Lilly's weight-loss drug to some patients
England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Becker's Hospital Review10d
Inside the GLP-1 'price war'
According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...
pharmaphorum1d
Older GLP-1 drug shows glimmer of benefit in Alzheimer's
It's possible that Alzheimer's disease could be added to the lengthening list of ... injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was ...
AOL1mon
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
The anti-obesity drug market could one day be worth $100 billion. It's a massive opportunity in healthcare, and two companies that are leaders in that space today are Eli Lilly (NYSE: LLY) and ...
The Business Journals22d
Insurance execs share what employers need to know about the craze for GLP-1 weight loss medications
According to a recent article in the American Journal of Managed Care, the list price for GLP-1 drugs can range from $936 to $1,349 before insurance and other discounts. Costs are rising so ...
NBC New York14d
Do GLP-1 supplements work? What to know about ‘nature's Ozempic'
The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here's what doctors think about them. Weight loss with Ozempic or Wegovy can be effective, but ...
Business Insider22d
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
The list price of one popular medication is $ ... Noom provides access to both compounded and brand-name GLP-1 medications,” continued Cook. “While we hope for a future of widely available ...
Becker's Hospital Review25d
Drugmakers say GLP-1 shortages are easing, but patients struggle to fill prescriptions
Novo Nordisk recently said its supply of its GLP-1 drugs has improved ... get Ozempic in the U.S. The FDA continues to list these drugs in shortage, requiring manufacturers to prove they can ...
The Daily Item22d
Ozempic, other GLP-1 drugs at center of sweeping class action that kicked off in Philadelphia
The plaintiffs' attorneys claim that GLP-1 drugs — specifically Ozempic ... the litigation against the pharmaceutical giants, 85% list gastroparesis as an alleged injury. Gastroparesis occurs ...
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...